Nutriband Inc. to Showcase AVERSA(TM) Technology at Emerging Growth Conference
Nutriband Inc. (NASDAQ: NTRB) will present its AVERSA(TM) abuse-deterrent technology at the Emerging Growth Conference, highlighting its potential to revolutionize transdermal pharmaceutical products.
Nutriband Inc. (NASDAQ: NTRB), a company at the forefront of developing abuse-deterrent transdermal pharmaceutical products, is set to make a significant appearance at the Emerging Growth Conference on August 20, 2025. The event will feature a live, interactive presentation by Chairman Serguei Melnik, who may also engage with shareholders and the investment community through a real-time Q&A session. This participation underscores Nutriband's commitment to advancing its AVERSA(TM) technology, designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The AVERSA(TM) technology represents a groundbreaking approach in the pharmaceutical industry, offering a solution to the growing concern over opioid abuse. By integrating this technology into transdermal patches, Nutriband aims to set a new standard for safety in drug delivery systems. The upcoming presentation at the Emerging Growth Conference provides a platform for the company to demonstrate the value and potential of its innovations to a broader audience. For more details on Nutriband's participation in the conference, visit https://ibn.fm/dhj3J.
Investors and stakeholders interested in following Nutriband's progress and updates can find the latest news in the company’s newsroom at https://ibn.fm/NTRB. This event is a pivotal moment for Nutriband as it seeks to expand its reach and impact in the pharmaceutical sector, leveraging the Emerging Growth Conference to highlight the importance of its AVERSA(TM) technology in addressing critical challenges in drug safety and abuse prevention.